Subpages Investors & Media Shares Presentations Share Issue Ownership Structure Corporate Governance Calendar Financial Reports Press Releases News Investors & Media Contact Subscribe Infant Bacterial Therapeutics CFO leaves the company
Infant Bacterial Therapeutics ABs CFO Daniel Mackey has decided to leave the company to pursue new challenges. He will remain in his current role during his notice period. Michael Owens will be...
May 20, 2021
IBT publishes annual report for 2018
Today, Infant Bacterial Therapeutics AB (publ) publishes the Annual Report for the financial year 2018. The report is available on IBT’s website ibtherapeutics.com under the...
April 4, 2019
Last patient enrolled in IBT’s Phase 2 study
Infant Bacterial Therapeutics AB (publ) (“IBT”) announces that the last premature infant has now been enrolled and recruitment to the Phase 2 study is now closed. The Phase 2 study...
January 24, 2017
Infant Bacterial Therapeutics AB appoints new CFO
Infant Bacterial Therapeutics AB (publ.) (“IBT”) is pleased to announce the appointment of Daniel Mackey as Chief Financial Officer (CFO) from January 2017 replacing Michael Owens in this role....
October 12, 2016
IBT’s rights issue fully subscribed
The result of Infant Bacterial Therapeutics AB’s (“IBT” or the “Company”) rights issue, for which the subscription period ended on 23 May 2016, indicates that 3,575,583 shares,...
May 26, 2016
IBT receives additional funding from BioGaia
Infant Bacterial Therapeutics plans to start a study on the safety and tolerability of the product in 2015. To allow for the study start, BioGaia will support IBT with an additional investment of 520...
March 26, 2015
Orphan Drug Designation in Europe
Infant Bacterial Therapeutics has now obtained the Orphan Drug Designation for Lactobacillus reuteri for the prevention of necrotizing enterocolitis in Europe.
Read the official press release here
February 23, 2015
FDA approves orphan drug designation
Necrotizing enterocolitis (NEC) is a rare and extremely severe disease that affects premature infants. The FDA Office of Orphan Product Development has approved the request. Read the official press...
February 21, 2014
BioGaia invests in a drug against NEC
The board of BioGaia has decided to invest in the first phase of a long-term project aimed at developing a drug with rigorous hygiene, analysis and documentation requirements, to treat the highly...
February 21, 2014